Gossamer Bio (NASDAQ:GOSS) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Friday morning,Benzinga reports. Wedbush currently has a $4.00 price objective on the stock.

Several other analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Tuesday, March 18th. The Goldman Sachs Group lowered their price target on Gossamer Bio from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, April 17th.

Gossamer Bio Trading Down 1.0%

Shares of GOSS opened at $1.04 on Friday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $236.31 million, a P/E ratio of -3.25 and a beta of 1.82. The stock’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $0.99. Gossamer Bio has a twelve month low of $0.50 and a twelve month high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $3.95 million. On average, equities research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Trading of Gossamer Bio

Several large investors have recently modified their holdings of GOSS. Octagon Capital Advisors LP grew its stake in shares of Gossamer Bio by 99.7% during the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after acquiring an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. grew its stake in shares of Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Monaco Asset Management SAM grew its stake in shares of Gossamer Bio by 39.5% during the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after acquiring an additional 1,520,721 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Gossamer Bio by 720.2% during the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after acquiring an additional 825,047 shares in the last quarter. Finally, Allostery Investments LP acquired a new stake in shares of Gossamer Bio during the fourth quarter valued at about $555,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.